Disease · MONDO_0009693

plasma cell myeloma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. plasma cell myeloma. Diseases, record MONDO_0009693. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0009693

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: plasma cell myeloma; Open Targets
Open Targets ID: MONDO_0009693; Open Targets
Other names: Kahler disease, Kahler's disease, Multiple Myeloma, medullary plasmacytoma, multiple myeloma, resistance to, Somatic mutation, multiple myeloma, susceptibility to, Somatic mutation, multiple myeloma/plasma cell myeloma, myeloid neoplasm of plasma cell, myeloma, myeloma, multiple, myeloma, plasma cell, malignant, myelomatosis, plasma cell myeloid neoplasm; Open Targets
Disease Ontology: DOID:9538; Disease Ontology
MeSH: D009101; MeSH
NCI Thesaurus: C3242; NCI Thesaurus
Orphanet: ORPHA:29073; Orphanet
Highest stage of its drugs: Approval, for 38 of its 553 drugs, from ClinicalTrials.gov, DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs553

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DEXAMETHASONE	CHEMBL384467	Small molecule	Approval	ClinicalTrials.gov, EMA Human Drugs and PMDA	856	852	851	Drugs and targets
LENALIDOMIDE	CHEMBL848	Small molecule	Approval	DailyMed, EMA Human Drugs and TTD	478	470	469	Drugs and targets
BORTEZOMIB	CHEMBL325041	Small molecule	Approval	EMA Human Drugs, PMDA and TTD	465	458	458	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Approval	DailyMed	239	235	234	Drugs and targets
DARATUMUMAB	CHEMBL1743007	Antibody	Approval	ClinicalTrials.gov, DailyMed, EMA Human Drugs, PMDA and TTD	233	228	226	Drugs and targets
MELPHALAN	CHEMBL852	Small molecule	Approval	DailyMed, EMA Human Drugs and TTD	221	217	217	Drugs and targets
POMALIDOMIDE	CHEMBL43452	Small molecule	Approval	ClinicalTrials.gov, DailyMed, EMA Human Drugs and PMDA	215	207	207	Drugs and targets
CARFILZOMIB	CHEMBL451887	Protein	Approval	ClinicalTrials.gov, DailyMed, EMA Human Drugs, PMDA and TTD	197	193	193	Drugs and targets
THALIDOMIDE	CHEMBL468	Small molecule	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	144	137	136	Drugs and targets
IXAZOMIB	CHEMBL2141296	Small molecule	Approval	EMA Human Drugs and TTD	80	78	78	Drugs and targets

1 to 10 of 553

See all 553 drugs

Targets446

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	16	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	14	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	14	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	14	Stem cell growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3815	Drugs and targets
NR3C1	Glucocorticoid receptor	14	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
TUBA1A	Tubulin	14	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	14	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	14	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	14	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	14	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/112714	Drugs and targets

1 to 10 of 446

See all 446 targets

Trials2,088

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 26 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00179647	Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma	Phase 3	1,913	2010-03-03	Multiple Myeloma	DEXAMETHASONE, LENALIDOMIDE	Its record names the disease	ClinicalTrials.gov
NCT00869206	Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement	Phase 3	1,822	2018-11-07	Breast Adenocarcinoma, DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, Metastatic Malignant Neoplasm to the Bone, Pain, Musculoskeletal Complication, Urinary Complications	ZOLEDRONIC ACID	Its record names the disease	ClinicalTrials.gov
NCT00330759	Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.	Phase 3	1,779	2014-04-09	Bone Metastases	DENOSUMAB, ZOLEDRONIC ACID	Its record names the disease	ClinicalTrials.gov
NCT01345019	Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma	Phase 3	1,718	2018-03-07	Cancer, Hematologic Malignancies, Multiple Myeloma, Oncology, Bone Metastases, Multiple Myeloma Bone Lesions	DENOSUMAB	Its record names the disease	ClinicalTrials.gov
NCT00689936	Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma	Phase 3	1,623	2017-08-11	Multiple Myeloma	DEXAMETHASONE, LENALIDOMIDE	Its record names the disease	ClinicalTrials.gov
NCT02541383	A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma	Phase 3	1,085	2025-04-13	Multiple Myeloma	BORTEZOMIB, DARATUMUMAB, DEXAMETHASONE, THALIDOMIDE	Its record names the disease	ClinicalTrials.gov
NCT01818752	Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma	Phase 3	955	2017-08-01	Multiple Myeloma	CARFILZOMIB, MELPHALAN, PREDNISONE	Its record names the disease	ClinicalTrials.gov
NCT01568866	Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients	Phase 3	929	2015-12-11	Multiple Myeloma	CARFILZOMIB, DEXAMETHASONE	Its record names the disease	ClinicalTrials.gov
NCT01080391	Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma	Phase 3	792	2015-07-08	Relapsed Multiple Myeloma	CARFILZOMIB, DEXAMETHASONE, LENALIDOMIDE	Its record names the disease	ClinicalTrials.gov
NCT03169361	NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refractory Multiple Myeloma"		774	2023-12-07	Relapsed/Refractory Multiple Myeloma	IXAZOMIB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 2,088

See all 2,088 trials

Comparisons in its trials438

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Zoledronic Acid 4 mg Q4W vs Denosumab 120 mg Q4W: serious adverse events	581 of 878	552 of 878	1,756	NCT00330759	Trial comparisons
Arm I (Zoledronic Acid Every 4 Weeks) vs Arm II (Zoledronic Acid Every 12 Weeks): deaths from any cause	41 of 879	42 of 868	1,747	NCT00869206	Trial comparisons
Arm I (Zoledronic Acid Every 4 Weeks) vs Arm II (Zoledronic Acid Every 12 Weeks): serious adverse events	96 of 879	103 of 868	1,747	NCT00869206	Trial comparisons
Arm A Part 1 vs Arm B Part 1: Post-Consolidation Stringent Complete Response (sCR) Rate	110 of 542	157 of 543	1,085	NCT02541383	Trial comparisons
Bortezomib, Melphalan, Prednisone vs Carfilzomib, Melphalan, Prednisone: serious adverse events	198 of 470	235 of 474	944	NCT01818752	Trial comparisons
Bortezomib vs Carfilzomib: serious adverse events	182 of 456	272 of 463	919	NCT01568866	Trial comparisons
Breast Cancer 4 Weeks vs Breast Cancer 12 Weeks: Proportion of Patients Having at Least One SRE Within 24 Months After Randomization for the Subgroups of Patients With Breast Cancer	113 of 410	119 of 410	820	NCT00869206	Trial comparisons
Lenalidomide and Dexamethasone (Rd) vs Carfilzomib, Lenalidomide, and Dexamethasone (CRd): serious adverse events	221 of 389	256 of 392	781	NCT01080391	Trial comparisons
PAN+BTZ vs PBO+BTZ: serious adverse events	228 of 381	157 of 377	758	NCT01023308	Trial comparisons
E-Ld Cohort vs Ld Cohort: deaths from any cause	240 of 374	232 of 374	748	NCT01335399	Trial comparisons

1 to 10 of 438

See all 438 comparisons in its trials

Papers from its trials1,089

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42097596	RESULT	1	PubMed
41556942	RESULT	1	PubMed
41038184	RESULT	1	PubMed
39755360	RESULT	1	PubMed
39540213	RESULT	1	PubMed
39055646	RESULT	1	PubMed
39001399	RESULT	1	PubMed
38937492	RESULT	1	PubMed
38889735	RESULT	1	PubMed
38717869	RESULT	1	PubMed

1 to 10 of 1,089

See all 1,089 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0009693

GET https://conductscience.org/api/diseases/v1/MONDO_0009693/drugs?page=2

API reference For AI assistants